With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.
The implementation of precision medicine represents a huge, possibly unprecedented, challenge to conventional clinical practice across the breadth of healthcare disciplines, says Daniel Lim of Kirkland & Ellis.
An EU court ruling on gene-editing regulation has sparked widespread concerns in the scientific and legal communities, as LSIPR finds out.
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports.
The patenting of personalised healthcare inventions has proved problematic in a number of jurisdictions, but various aspects of these inventions are patentable in Europe, as Laurence Gainey of HGF explains.
Depending on the facts and the content of the applications, an Arrow-type declaration could be made on grounds of insufficiency against divisional applications, say David Holt and Tony Proctor of Potter Clarkson.
BIO-Europe heads to Scandinavia for the first time, as Copenhagen plays host in November. LSIPR finds out more.
Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
The Milan Court has issued an important ruling clarifying the rules governing the activities of active pharmaceutical ingredient manufacturers in Italy, as Gabriel Cuonzo and Luca Pellicciari of Trevisan & Cuonzo report.
Frank Kalkbrenner was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.